Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689990 | 1.00 | ACHE (0.62) | ACHELMNASLC6A4DRD2DRD4 | |
| SCHEMBL29567963 | 1.00 | ACHE (0.62) | ACHELMNASLC6A4DRD2DRD4 | |
| Bromide SCHEMBL9067059 | 0.98 | ACHE (0.60) | ACHELMNASLC6A4DRD2DRD4 | |
| SCHEMBL16830451 | 0.98 | ACHE (0.60) | ACHELMNASLC6A4DRD2DRD4 | |
| SCHEMBL4160738 | 0.91 | LMNA (0.53) | ACHELMNASLC6A4DRD2DRD4 | |
| SCHEMBL4557182 | 0.85 | LMNA (0.54) | ACHELMNASLC6A4SIGMAR1HTR6 | |
| SCHEMBL3921135 | 0.84 | ACHE (0.68) | ACHELMNADRD2DRD4DRD3 | |
| SCHEMBL31392633 | 0.84 | ACHE (0.68) | ACHEDRD2DRD4DRD3TSHR | |
| SCHEMBL2378007 | 0.83 | TDP1 (0.55) | LMNASLC6A4SIGMAR1HTR6TSHR | |
| Formic Acid SCHEMBL4823937 | 0.83 | ACHE (0.46) | ACHELMNASLC6A4HTR6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230407244-A1 | MICROBIAL GROWTH-STIMULATING PROTEIN AND METHODS OF USING SAME | PARADIGM DIAGNOSTICS, INC. (US) | 2023-12-21 | — | — | US | claimed |
| CN-116768826-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2023-09-19 | — | — | CN | claimed |
| US-11732285-B2 | Selective enrichment media and uses thereof | PARADIGM DIAGNOSTICS, INC. (US) | 2023-08-22 | — | — | US | claimed |
| WO-2022093775-A1 | MICROBIAL GROWTH-STIMULATING PROTEIN AND METHODS OF USING SAME | PARADIGM DIAGNOSTICS, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| US-20200208099-A1 | SELECTIVE ENRICHMENT MEDIA AND USES THEREOF | PARADIGM DIAGNOSTICS, INC. (US) | 2020-07-02 | — | — | US | claimed |
| US-10619130-B1 | Selective enrichment media and uses thereof | PARADIGM DIAGNOSTICS, INC. (US) | 2020-04-14 | — | — | US | claimed |
| US-20170095502-A1 | Antimicrobial Metal-Binding Polymers | SARANGAPANI SHANTHA (US) | 2017-04-06 | — | — | US | claimed |
| US-9518283-B1 | Selective enrichment media and uses thereof | PARADIGM DIAGNOSTICS, INC. (US) | 2016-12-13 | — | — | US | claimed |
| US-9029118-B1 | Selective enrichment media and uses thereof | PARADIGM DIAGNOSTICS, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-20100119525-A1 | METHOD FOR EXTENDING LONGEVITY USING NPC1L1 ANTAGONISTS | MOUNT SINAI SCHOOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2010-05-13 | — | — | US | claimed |
| EP-1789437-A4 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | SINAI SCHOOL MEDICINE (US) | 2008-11-05 | — | — | EP | claimed |
| EP-1789437-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | Mount Sinai School of Medicine of New York University (US) | 2007-05-30 | — | — | EP | claimed |
| WO-2007016643-A2 | A METHOD FOR EXTENDING LONGEVITY USING NPC1L1 ANTAGONISTS | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2007-02-08 | — | — | WO | claimed |
| WO-2006015365-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2006-02-09 | — | — | WO | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-4115569-A | PARASITICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-19 | — | — | US | disclosed |
| US-4112092-A | CNS DISORDER, PARKINSON'S, CARDIOVASCULAR DISORDER | SCIENCE UNION ET CIE (FR) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACHE 2240/4885LMNA 1538/4885SLC6A4 2169/4885 |
| US-20100119525-A1 | METHOD FOR EXTENDING LONGEVITY USING NPC1L1 ANTAGONISTS | NPC1L1, LIPA, LPL | ACHE 2797/4885LMNA 389/4885SLC6A4 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.